SCHEMBL3975181

SCHEMBL3975181

CC(=O)c1ccc(C(=O)NCCc2ccccc2)s1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 3/20 0.68
HDAC3 O15379 1/20 0.68
HDAC4 P56524 1/20 0.68
HDAC1 Q13547 1/20 0.68
NPC1 O15118 10/20 0.62
RAB9A P51151 10/20 0.62
SMN1; SMN2 Q16637 7/20 0.62
L3MBTL1 Q9Y468 2/20 0.62
USP2 O75604 1/20 0.62
AKT3 Q9Y243 1/20 0.55
ALDH1A1 P00352 2/20 0.55
LMNA P02545 2/20 0.52
MEN1 O00255 1/20 0.52
GAA P10253 1/20 0.52
MAPT P10636 1/20 0.52
KMT2A Q03164 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
CLK1 P49759 1/20 0.52
HDAC2 Q92769 1/20 0.51
HDAC8 Q9BY41 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6455155 0.85 HDAC3 (0.65) HDAC6HDAC3HDAC4HDAC1NPC1
SCHEMBL13992634 0.85 NPC1 (0.75) HDAC6HDAC3HDAC4HDAC1NPC1
SCHEMBL3973531 0.84 HDAC6 (0.67) HDAC6HDAC3HDAC4HDAC1NPC1
SCHEMBL4923585 0.82 NPC1 (0.74) HDAC6HDAC3HDAC4HDAC1NPC1
SCHEMBL14100173 0.82 RAB9A (0.57) RAB9AALDH1A1LMNAMAPTCLK1
SCHEMBL4774806 0.81 HDAC1 (1.00) HDAC6HDAC3HDAC4HDAC1NPC1
SCHEMBL3973421 0.80 HDAC3 (0.58) HDAC6HDAC3HDAC4HDAC1NPC1
SCHEMBL3973430 0.80 HDAC3 (0.58) HDAC6HDAC3HDAC4HDAC1NPC1
SCHEMBL6360616 0.79 GSK3B (0.53) HDAC6HDAC3HDAC4HDAC1NPC1
SCHEMBL7818276 0.79 NPC1 (0.47) HDAC6HDAC3HDAC4HDAC1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1907385-A4 COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2009-05-06 EP disclosed
US-20080194561-A1 carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. SMITHKLINE BEECHAM CORPORATION 2008-08-14 US disclosed
US-20080194561-A1 carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. SMITHKLINE BEECHAM CORPORATION 2008-08-14 US disclosed
US-20080194561-A1 carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. SMITHKLINE BEECHAM CORPORATION 2008-08-14 US disclosed
EP-1907385-A2 COMPOUNDS SmithKline Beecham Corporation (US) 2008-04-09 EP disclosed
WO-2007018941-A2 PYRIMIDYL-THIOPHENE DERIVATIVES SMITHKLINE BEECHAM CORPORATION (US) 2007-02-15 WO disclosed
WO-2007018941-A2 PYRIMIDYL-THIOPHENE DERIVATIVES SMITHKLINE BEECHAM CORPORATION (US) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194561-A1 carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. AURKA, AURKC, AURKB HDAC6 1330/4885HDAC3 1847/4885HDAC4 1732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.